In the future, the combined use of GLP-1RAs and GLP-1 releasers, which have distinct mechanisms of action and effects, may contribute to the development of a long-term and effective strategy for obesity treatment and prevention. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.